Oyster Point Pharma, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2015-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.oysterpointrx.com
Clinical Trial to Evaluate the Efficacy of OC-02 Nasal Spray on Signs and Symptoms of Dry Eye Disease (The PEARL Study)
Phase 2
Completed
- Conditions
- Dry Eye Disease
- Interventions
- Drug: 0.2 % hemigalactarate (0.11% free base) 0.2 % OC-02 Low Dose (1.1 mg/mL)Drug: 2.0 % hemigalactarate (0.11% free base) 2.0 % OC-02 High Dose (11.1 mg/mL)Drug: Placebo (vehicle) nasal sprayDrug: 1.0 % hemigalactarate (0.11% free base) 1.0 % OC-02 Mid Dose (5.5 mg/mL)
- First Posted Date
- 2018-03-02
- Last Posted Date
- 2021-12-14
- Lead Sponsor
- Oyster Point Pharma, Inc.
- Target Recruit Count
- 165
- Registration Number
- NCT03452397
- Locations
- 🇺🇸
Andover, Andover, Massachusetts, United States
🇺🇸Nashville, Nashville, Tennessee, United States
🇺🇸Louisville, Louisville, Kentucky, United States
© Copyright 2025. All Rights Reserved by MedPath